Mélatonine : aspects physiologiques et pharmacologiques en relation avec le sommeil, intérêt d’une forme galénique à libération prolongée (Circadin®) dans l’insomnie

Lerner, 1958, Isolation of melatonin, the pineal gland factor that lightens melanocytes, J Am Chem Soc, 80, 2587, 10.1021/ja01543a060 Moore, 1992, The fourth C.U. Ariens Kappers lecture. The organization of the human circadian timing system, Prog Brain Res, 93, 99, 10.1016/S0079-6123(08)64566-5 Brainard, 2001, Action spectrum for melatonin regulation in humans: evidence for a novel circadian photoreceptor, J Neurosci, 21, 6405, 10.1523/JNEUROSCI.21-16-06405.2001 Moller, 2002, The anatomy and innervation of the mammalian pineal gland, Cell Tissue Res, 309, 139, 10.1007/s00441-002-0580-5 Lewy, 1980, Light suppresses melatonin secretion in humans, Science, 210, 1267, 10.1126/science.7434030 Cajochen, 2011, Evening exposure to a light-emitting diodes (LED)-backlit computer screen affects circadian physiology and cognitive performance, J Applied Physiol, 110, 1432, 10.1152/japplphysiol.00165.2011 Le Bars, 1991, PET and plasma pharmacokinetic studies after bolus intravenous administration of 11C melatonin in humans, Nucl Med Biol, 18, 357 Iguchi, 1982, Melatonin serum levels and metabolic clearance rate in patients with liver cirrhosis, J Clin Endocrinol Metab, 54, 1025, 10.1210/jcem-54-5-1025 Di, 1997, Variable bioavailability of oral melatonin, N Engl J Med, 336, 1028, 10.1056/NEJM199704033361418 Härtter, 2006, Effect of caffeine intake 12 or 24 hours prior to melatonin intake and CYP1A2*1F polymorphism on CYP1A2 phenotyping by melatonin, Basic Clin Pharmacol Toxicol, 99, 300, 10.1111/j.1742-7843.2006.pto_491.x Claustrat, 2005, The basic physiology and pathophysiology of melatonin, Sleep Med Rev, 9, 11, 10.1016/j.smrv.2004.08.001 Dubocovich, 2010, International Union of Basic and Clinical pharmacology. LXXV. Nomenclature, classification, and pharmacology of G protein-coupled melatonin receptors, Pharmacol Rev, 62, 343, 10.1124/pr.110.002832 Liu, 2016, MT1 and MT2 melatonin receptors: a therapeutic perspective, Annu Rev Pharmacol Toxicol, 56, 361, 10.1146/annurev-pharmtox-010814-124742 Ekmekcioglu, 2006, Melatonin receptors in humans: biological role and clinical relevance, Biomed Pharmacother, 60, 97, 10.1016/j.biopha.2006.01.002 Kamal, 2015, Convergence of melatonin and serotonin (5-HT) signaling at MT2/5-HT2C receptor heteromers, J Biol Chem, 290, 11537, 10.1074/jbc.M114.559542 Poirel, 2002, MT1 melatonin receptor mRNA expression exhibits a circadian variation in the rat suprachiasmatic nuclei, Brain Res, 946, 64, 10.1016/S0006-8993(02)02824-X Skene, 2007, Circadian rhythm sleep disorders in the blind and their treatment with melatonin, Sleep Med, 8, 651, 10.1016/j.sleep.2006.11.013 Krauchi, 1997, A relationship between heat loss and sleepiness: effects of postural change and melatonin administration, J Appl Physiol, 83, 134, 10.1152/jappl.1997.83.1.134 Lack, 2008, The relationship between insomnia and body temperatures, Sleep Med Rev, 12, 307, 10.1016/j.smrv.2008.02.003 Wang, 2003, The GABA(A) receptor mediates the hypnotic activity of melatonin in rats, Pharmacol Biochem Behav, 74, 573, 10.1016/S0091-3057(02)01045-6 Nave, 1996, Hypnotic and hypothermic effects of melatonin on daytime sleep in humans: lack of antagonism by flumazenil, Neurosci Lett, 214, 123, 10.1016/0304-3940(96)12899-8 Cajochen, 1996, Daytime melatonin administration enhances sleepiness and thêta/alpha activity in the waking EEG, Neurosci Lett, 207, 209, 10.1016/0304-3940(96)12517-9 Lavie, 1997, Melatonin: role in gating nocturnal rise in sleep propensity, J Biol Rhythms, 12, 657, 10.1177/074873049701200622 Quera-Salva, 2011, Circadian rhythm disturbances associated with psychiatric symptoms in a patient with a pineal region tumor, Am J Psychiatry, 168, 99, 10.1176/appi.ajp.2010.10101440 Gorfine, 2007, Nap and melatonin-induced changes in hippocampal activation and their role in verbal memory consolidation, J Pineal Res, 43, 336, 10.1111/j.1600-079X.2007.00482.x Aeschbach, 2003, A longer biological night in long sleepers than in short sleepers, J Clin Endocrinol Metab, 88, 26, 10.1210/jc.2002-020827 Lewy, 1992, Melatonin shifts human circadian rhythms according to a phase-response curve, Chronobiol Int, 9, 380, 10.3109/07420529209064550 Zaidan, 1994, Melatonin in able to influence its secretion in humans: description of a phase-response curve, Neuroendocrinology, 60, 105, 10.1159/000126726 Deacon, 1994, Acute phase-shifting effects of melatonin associated with suppression of core body temperature in humans, Neurosci Lett, 178, 32, 10.1016/0304-3940(94)90282-8 Garfinkel, 1995, Improvement of sleep quality in elderly people by controlled-release melatonin, Lancet, 346, 541, 10.1016/S0140-6736(95)91382-3 Buscemi, 2005, The efficacy and safety of exogenous melatonin for primary sleep disorders. A meta-analysis, J Gen Intern Med, 20, 1151, 10.1111/j.1525-1497.2005.0243.x Zhdanova, 1997, Efficacy of melatonin as a sleep-promoting agent, J Biol Rhythms, 12, 644, 10.1177/074873049701200620 Haimov, 1994, Sleep disorders and melatonin rhythms in elderly people, Br Med J, 309, 167, 10.1136/bmj.309.6948.167 Bumb, 2014, Pineal gland volume in primary insomnia and healthy controls: a magnetic resonance imaging study, J Sleep Res, 23, 274, 10.1111/jsr.12125 Lemoine, 2007, Prolonged-release melatonin improves sleep quality and morning alertness in insomnia patients aged 55 years and older and has no withdrawal effects, J Sleep Res, 16, 372, 10.1111/j.1365-2869.2007.00613.x Wade, 2010, Nightly treatment of primary insomnia with prolonged-release melatonin for 6 months: a randomized placebo-controlled trial on age and endogenous melatonin as predictors of efficacy and safety, BMC Med, 8, 51, 10.1186/1741-7015-8-51 Buysse, 1989, The Pittsburgh sleep quality index: a new instrument for psychiatric practice and research, Psychiatry Res, 28, 193, 10.1016/0165-1781(89)90047-4 Zisapel, 2003, Determination of the minimal clinically significant difference on a patient visual analog sleep quality scale, J Sleep Res, 12, 291, 10.1046/j.0962-1105.2003.00365.x Wade, 2007, Efficacy of prolonged-release melatonin in insomnia patients aged 55–80 years: quality of sleep and next-day alertness outcomes, Curr Med Res Opin, 23, 2597, 10.1185/030079907X233098 Luthringer, 2009, The effect of prolonged-release melatonin on sleep measures and psychomotor performance in elderly patients with insomnia, Int Clin Psychopharmacol, 24, 239, 10.1097/YIC.0b013e32832e9b08 Lemoine, 2011, Prolonged-release melatonin for insomnia – an open-label long-term study of efficacy, safety, and withdrawal, Ther Clin Risk Manag, 7, 301 Leger, 2004, Nocturnal 6-sulfatoxymelatonin excretion in insomnia and its relation to the response to melatonin replacement therapy, Am J Med, 116, 91, 10.1016/j.amjmed.2003.07.017 Garfinkel, 2011, Efficacy and safety of prolonged-release melatonin in insomnia patients with diabetes: a randomized, double-blind, crossover study, Diabetes Metab Syndr Obes, 4, 307 Lemoine, 2012, Efficacy and safety of prolonged-release melatonin for insomnia in middle-aged and elderly patients with hypertension: a combined analysis of controlled clinical trials, Integr Blood Press Control, 5, 9 Otmani, 2008, Effects of prolonged-release melatonin, zolpidem, and their combination on psychomotor functions, memory recall, and driving skills in healthy middle-aged and elderly volunteers, Hum Psychopharmacol Clin Exp, 23, 693, 10.1002/hup.980 Arbon, 2015, Randomised clinical trial of the effects of prolonged-release melatonin, temazepam and zolpidem on slow-wave activity during sleep in healthy people, J Psychopharmacol, 7, 764, 10.1177/0269881115581963 Kunz, 2012, Benzodiazepine discontinuation with prolonged-release melatonin: hints from a German longitudinal prescription database, Expert Opin Pharmacother, 13, 9, 10.1517/14656566.2012.638284 Hajak, 2015, Lasting treatment effects in a postmarketing surveillance study of prolonged-release melatonin, Inter Clin Psychopharmacol, 30, 36, 10.1097/YIC.0000000000000046 Quera-Salva, 2017, Non-24-hour sleep-wake rhythm disorder in the totally blind: diagnosis and management, Front Neurol, 8, 686, 10.3389/fneur.2017.00686 Roth, 2015, Prolonged-release melatonin for improving sleep in totally blind subjects: a pilot placebo-controlled multicenter trial, Nat Sci Sleep, 7, 13 Grima, 2018, Efficacy of melatonin for sleep disturbance following traumatic brain injury: a randomised controlled trial, BMC Med, 16, 8, 10.1186/s12916-017-0995-1 Gringras, 2017, Efficacy and safety of pediatric prolonged-released melatonin for insomnia in children with autism spectrum disorder, J Am Acad Child Adolesc Psychiatry, 56, 948, 10.1016/j.jaac.2017.09.414 Cardinali, 1998, Basic aspects of melatonin action, Sleep Med Rev, 2, 175, 10.1016/S1087-0792(98)90020-X Zisapel, 2010, Melatonin and sleep, Open Neuroendocrinol J, 3, 85